Gerresheimer AG: Gerresheimer reports strong second quarter
DGAP-News: Gerresheimer AG / Key word(s): Quarterly / Interim Statement
Gerresheimer reports strong second quarter
- Revenues up 7.2% on the prior-year quarter to EUR 356.5m
- Adjusted EBITDA at EUR 74.2m in second quarter of 2019 (Q2 2018: EUR 71.1m), excluding EUR 26.2m from derecognition of contingent purchase price components in connection with Sensile Medical acquisition
- Revenue guidance confirmed without change; guidance on adjusted EBITDA at constant exchange rates for the financial year 2019 approximately EUR 295m (plus or minus EUR 5m), excluding EUR 118.5m from derecognition of contingent purchase price components from Sensile Medical acquisition in the first half year
- Adjusted earnings per share increased to EUR 1.87
- New project at Sensile Medical: micro pump for treatment of heart failure
Duesseldorf, July 11, 2019-Gerresheimer AG closed the second quarter of the financial year 2019 (March 1, 2019 to May 31, 2019) with strong revenue growth. "We had a successful second quarter. Our business retains its strong momentum. All divisions contributed to the good revenue growth. I am confident that we will meet all of our targets for 2019. Sensile Medical's micro pump for Parkinson's treatment is successfully in use in the European market and is progressing positively. The groundwork is also now being laid in a highly promising new project for the treatment of heart failure," said Dietmar Siemssen, CEO of Gerresheimer AG.
Gerresheimer increased revenues by 7.2% to EUR 356.5m in the second quarter of the financial year 2019, up from EUR 332.6m in the prior-year quarter. The syringe business performed well in the second quarter of 2019. Revenues with plastic primary pharmaceutical packaging also grew. The medical plastic systems business was stable. Moulded glass primary packaging revenues increased, mainly due to a rise in demand from cosmetics customers. The injection vial, ampoule and cartridge business did particularly well in Europe and Asia.
Gerresheimer is pursuing a large number of projects for profitable growth and enhanced productivity. These projects are being systematically implemented and are well on schedule. They include the expansion of syringe production at the plant in Buende, Germany, and expansion of the pharmaceutical primary plastic packaging plant in Anapolis, Brazil. The moulded glass plant in Essen, Germany, is to undergo a furnace overhaul in conjunction with capacity expansion and further automation.
In figures, capital expenditure of EUR 28.6m was incurred in the second quarter of 2019. This was mainly directed at the continued expansion of inhaler production capacity at the Horsovsky Tyn plant in the Czech Republic together with other additions to production capacity and to the product portfolio. Other capital expenditure in the quarter under review related to the prepayments for the furnace overhaul in Essen, Germany, as well as production plant modernization and automation at various plants.
Subsidiary Sensile Medical also made progress: The wearable micro infusion pump specially developed by Sensile Medical for EVER Pharma has already been commercialized for Parkinson's treatment in several European countries. The micro pump allows Parkinson's sufferers greater independence in their daily lives. The broad application range of the micro pump and of its modular standard engineering is demonstrated by a highly promising new project with great market potential. The micro pump is to be used in the treatment of heart failure. At present, the groundwork for this new project is being laid.
Adjusted EBITDA increased from EUR 71.1m in the prior-year quarter to EUR 74.2m in the second quarter of 2019. This does not include the EUR 26.2m relating to the derecognition of contingent purchase price components from the Sensile Medical acquisition.
Net income in the second quarter of 2019 was EUR 47.1m, compared to EUR 19.3m in the prior-year quarter. Adjusted net income after non-controlling interests amounted to EUR 58.7m, compared to a prior-year figure of EUR 26.0m. The figure for the second quarter of 2019 was influenced by the positive effect from the derecognition of contingent purchase price components. Adjusted earnings per share after non-controlling interests came to EUR 1.87 in the second quarter of 2019, compared to a prior-year figure of EUR 0.83.
Adjusted EBITDA leverage (net financial debt to adjusted EBITDA over the last twelve months) temporarily decreased to 2.3x. The decrease relates to the higher adjusted EBITDA.
- Revenues are expected to be in the range of approximately EUR 1.4bn to EUR 1.45bn in the financial year 2019.
- For adjusted EBITDA, the Company expects a figure of approximately EUR 295m in the financial year 2019 (plus or minus EUR 5m), versus a comparative figure of EUR 289.1m in the financial year 2018. This does not include EUR 118.5m in other operating income already recognized in the first half of 2019 due to derecognition of contingent purchase price components from the Sensile Medical acquisition.
- Capital expenditure as a percentage of revenues will be approximately 12% in 2019.
The medium-term indications published on February 14, 2019 remain unchanged.
The full quarterly report is available here:
Gerresheimer is a leading global partner to the pharma and healthcare industries. The company's special glass and plastic products contribute to health and well-being. Gerresheimer is a global organization with about 10,000 employees and manufacturing operations in the local markets, close to customers. With plants in Europe, North and South America and Asia Gerresheimer generates revenues of approximately EUR 1.4 billion. The comprehensive product portfolio includes pharmaceutical packaging products as well as convenient and safe drug delivery systems such as insulin pens, inhalers, micro pumps, prefillable syringes, vials, ampoules, bottles and containers for liquid and solid pharmaceuticals with closure and safety systems, plus cosmetic packaging products.
2 Excluding revenues of EUR 1.0m in the second quarter 2018 from the lost inhaler contract with a customer at our plant in Kuessnacht (Switzerland), the growth rate at constant exchange rates would have been 5.8 %.
3 Adjusted EBITDA: Net income before income taxes, net finance expense, amortization of fair value adjustments, depreciation and amortization, impairment losses, restructuring expenses, and one-off income and expenses.
4 The non-recurring other operating income of EUR 26.2m resulted from the derecognition of contingent purchase price components from the Sensile Medical acquisition.
5 Adjusted net income after non-controlling interests: Net income after non-controlling interests before non-cash amortization of fair value adjustments, non-recurring effects of restructuring expenses, portfolio adjustments, the balance of one-off income and expenses-including significant non-cash expenses-and the related tax effects.
6 Adjusted earnings per share after non-controlling interests divided by 31.4m shares.
7 Change calculated on a EUR k basis.
11.07.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||839753|
|End of News||DGAP News Service|